Stephen Malcolm Gillis

Introgen Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company develops molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. The company maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. It was founded in June 1993 and is headquartered in Austin, TX.

EDS provides a broad portfolio of business and technology solutions to help its clients worldwide improve their business performance. EDS’ core portfolio comprises information-technology, applications and business process services, as well as information-technology transformation services. EDS’ A.T. Kearney subsidiary is one of the world’s leading high-value management consultancies

Unidym, Inc. manufactures, develops, and applies carbon nanotubes. It also provides bulk materials to customers and business partners. The company was founded in 2005 and is headquartered in Sunnyvale, CA.

Cormedics Corp. develops novel technologies that selectively treat the entire heart with drug, cell, gene, and device therapies. The private company is based in Houston, TX. The CEO of the company is James W. Meador.